

# Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen

Friedrich Vogel, Karl-F. Bodmann und die Expertenkommission der Paul-Ehrlich-Gesellschaft

*Chemother J* 2004;13:46-105.

## Literatur

### Kapitel 1 - Einführung

BSG vom 19.3.2002, AZ: 1 KR 37/00 Bundesgesundheitsblatt 2003;46:458-61.  
 Dierks C. Legal implications of guidelines. *Dtsch Med Wochenschr* 2003;128:815-9.  
 Sachett DL, Rosenberg W, Moir M, Gray JA. Evidence based medicine: what it is and what it is not. *BMJ* 1996;312:71-2.  
 Schmitz S, Kleeberg UR, Seber S, et al. Wenn Therapiekosten zum Zankapfel werden. *Dtsch Arztebl* 2003;100:1657-9.  
 SIGN - Scottish Intercollegiate Guidelines Network. SIGN Guidelines - an introduction to sign methodology for the development of evidence-based clinical guidelines. SIGN Publication 1999:39.

### Kapitel 3 - Pharmakologie/Toxikologie

Frossard M, Joukhar C, Erovic BM, Dittich P, et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. *Antimicrob Agents Chemother* 2000;44:2728-32.

### Kapitel 4 - Atemwegsinfektionen

Adam D, Görtz G, Helwig H, Knothe H, et al. Empfehlungen der Expertenkommission Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.: Rationaler Einsatz oraler Antibiotika in der Praxis. *Chemother J* 1993;4:184-92.  
 American Hospital Association. Management advisory health care delivery: immunization. American Hospital Association Technical Panel on Infections within Hospitals. *Am J Infect Control* 1994;22:42-6.  
 American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. *Am Rev Respir* 1993;148:1418-26.  
 American Thoracic Society. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. *Am J Respir Crit Care Med* 1996;153:1711-25.  
 Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196-204.  
 Arancibia F, Bauer TT, Ewig S, Mensa J, et al. Community-acquired pneumonia due to gram-negative bacteria and *Pseudomonas aeruginosa*:

Incidence, risk, and prognosis. *Arch Intern Med* 2002;162:1849-58.  
 Bailey R, Weingarten S, Lewis M, Mohsenifar Z. Impact of clinical pathways and practice guidelines on the management of acute exacerbations of bronchial asthma. *Chest* 1998;113:28-33.  
 Ball P, Make B. Acute exacerbations of chronic bronchitis: An international comparison. *Chest* 1998;113(Suppl. 3):199-204.  
 Ball P. Epidemiology of treatment of chronic bronchitis and its exacerbations. *Chest* 1995;108:43-52.  
 Balter M, Grossman RF. Management of chronic bronchitis and acute exacerbations of chronic bronchitis. *Int J Antimicrob Agents* 1997;9:83-93.  
 Barnes PJ. Chronic obstructive pulmonary disease. *N Engl J Med* 2000;343:269-80.  
 Bartlett J. Treatment of CAP. *Chemotherapy* 2000;46(Suppl. 1):24-31.  
 Bartlett JG, et al. Practice guidelines for the management of community acquired pneumonia in adults. *Clin Infect Dis* 2000;31:347-82.  
 Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. *Clin Infect Dis* 1998;26:811-38.  
 Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. *Infectious Diseases Society of America Clin Infect Dis* 2000;31:347-82.  
 Bartlett JG, et al. Consensus on early intervention in community-acquired pneumonia: Panel Discussion. *Infect Dis Clin Pract* 1996;5(Suppl. 4):174-8.  
 Bartlett JG. Lower respiratory tract infections. *Infect Dis Clin Pract* 1996;5:147-67.  
 Bartlett JG. Management of upper respiratory tract infections. *Infect Dis Clin Pract* 1997;6:212-20.  
 Bartlett JG, Hillman AL, Niederman MS, Schwartz S. Clinical and economic consensus on early intervention in community-acquired pneumonia. *Inf Dis Clin Pract* 1996;5(Suppl. 4):S179-S184.  
 Bates JH, et al. Microbial etiology of acute pneumonia in hospitalized patients. *Chest* 1992;101:1005-12.  
 Bodmann KF, Lorenz J, Bauer TT, Ewig S, et al. Nosokomiale Pneumonie: Prävention, Diagnostik und Therapie. *Chemother J* 2003;12:33-44.  
 Bratzler DW, Houck PM, Nsa W, et al. Initial processes of care and outcomes in elderly patients with pneumonia. (abstract) American College of Emergency Physicians Research Forum, October 15, 2001, Chicago, IL.  
 British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. *Br J Hosp Med*

1993;49:346-50.  
 BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. *Thorax* 1997;52(Suppl. 5):16-21.  
 Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant *Streptococcus pneumoniae* in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. *J Infect Dis* 1996;174:986-93.  
 Campbell Jr GD, Niederman MS, Broughton WA, Craven DE, et al. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: A consensus statement. *Am J Res Crit Care Med* 1996;153:1711-25.  
 Cassiere HA, Niederman MS. Severe community-acquired pneumonia in an elderly patient *Chest* 1996;109:1645-8.  
 Celli BR. ATS standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Eur Respir Rev* 1996;6:276-81.  
 Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among adults aged 65 years United States, 1997. *MMWR Morb Mortal Wkly Rep* 1998;47:797-802.  
 Centers for Disease Control and Prevention. Pneumonia and influenza death rates United States, 1979-1994. *MMWR Morb Mortal Wkly Rep* 1995;44:535-7.  
 Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 1998;47:1-13.  
 Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP). *MMWR Morb Mortal Wkly Rep* 1997;46:1-24.  
 Centers for Disease Control. Pneumonia and influenza mortality in the United States, 1988-1989 season. *MMWR Morb Mortal Wkly Rep* 1989;38:97.  
 Chan R, Hemeryck L, O'Regan M, Clancy L, et al. Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. *Br Med J* 1995;310:1360-2.  
 Colice GL, et al. Medical and surgical treatment of parapneumonic effusions: an evidenced-based guideline. *Chest* 2000;118:1158-71. Erratum: *Chest* 2001;119:319.  
 Davies RJO, Gleeson FV. The diagnosis and management of pleural empyema. *Curr Opin Infect Dis* 1998;11:163-8.  
 Dewan NA, Rafique S, Kanwar B, Satpathy H, et al. Acute exacerbation of COPD: Factors associated with poor treatment outcome. *Chest* 2000;117:662-71.  
 Dietrich ES, Joseph U, Vogel F, Howaldt S, et al. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treat-

- ment of pneumonia in general medical wards in Germany. *Infection* 1999;27:148–54.
- Dicker RC, Han LF, Macone JJ. Quality of care surveillance using administrative data, 1996. Quality resume, no. 2. Baltimore, Maryland: Health Care Financing Administration, 1998.
- Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients in the United States during the wintermonths of 1994 to 1995: results of a 30-center national surveillance study. *Antimicrob Agents Chemother* 1996;40:1208–13.
- Eller J, Ede A, Schaberg T, Niederman MS, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. *Chest* 1998;113:1542–8.
- Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: Limited yield, minimal impact on treatment decisions. *Chest* 2002;121:1486–92.
- Farr BM, et al. Prediction of microbial etiology at admission to hospital for pneumonia from presenting clinical features. *Thorax* 1989;44:1031–5.
- Feiken DR, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–97. *Am J Public Health* 2000;90:223–9.
- Fein AM, Niederman MS. Severe pneumonia in the elderly. *Clinics Ger Med* 1994;10:121–43.
- Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. *Drugs* 1998;55:31–45.
- Fine MJ, et al. A prediction rule to identify low risk patients with CAP. *N Engl J Med* 1997;336:243–50.
- Fine MJ, et al. The hospital admission decision for patients with CAP. *Arch Intern Med* 1997;157:36–44.
- Fine MJ, Auble TE, Yealy DM, Hanusa BH, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;336:243–50.
- Fine MJ, Smith MA, Carson CA, Mutha SS, et al. Prognosis and outcomes of patients with community-acquired pneumonia. *JAMA* 1996;275:134–41.
- Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalizations for pneumonia in the elderly. *Am J Epidemiol* 1992;136:296–307.
- Friedland IR. Comparison of the response to antimicrobial treatment of penicillin resistant and penicillin susceptible pneumococcal disease. *Pediatr Infect Dis* 1995;14:885–90.
- Gleason PP, Kapoor WN, Stone RA, Lave JR, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. *JAMA* 1997;278:32–9.
- Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial regimens and medical outcomes for elderly patients with pneumonia. *Arch Intern Med* 1999;159:2562–72.
- Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. *Chest* 1997;112(Suppl):310–3.
- Grossmann RF, Campbell DA, Landis SJ, Garber GE, et al. Treatment of community-acquired pneumonia in the elderly: the role of Cefepime, a fourth-generation cephalosporin. *J Antimicrob Chemother* 1999;43:549–54.
- Hadlock C, Niederman MS, Stelmach WJ, Brown RB, et al. Clinical pathways in an acute care setting: Community-acquired pneumonia. *Infect Dis Clin Pract* 1996;5(Suppl. 4):S166–S173.
- Health Care Financing Administration. 1995 Data Compendium. Baltimore, Md: US Department of Health and Human Services, Health Care Financing Administration; 1995:75. HCFA No. 03364.
- Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, et al. Management of community acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant *Streptococcus pneumoniae* Therapeutic Working Group. *Arch Int Med* 2000;160:1399–408.
- Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states, 1993, 1995, and 1997. *Chest* 2001;119:1420–6.
- Houck PM, Bratzler DW, Niederman M, Bartlett JG. Pneumonia treatment process and quality. *Arch Intern Med* 2002;162:843–4.
- Kahn KL, Rogers WH, Rubenstein LV, et al. Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system. *JAMA* 1990;264:1969–73.
- Kauppinen MT, Saikku P, Kujala P, Herva E, et al. Clinical picture of community-acquired *Chlamydia pneumoniae* requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. *Thorax* 1996;51:185–9.
- Kries R von, Siedler A, Schmitt HJ. Epidemiologie von Pneumokokken-Infektionen bei Kindern. *Kinderärztl Prax* 2000;71:435–8.
- Leroy O, et al. A 5 year study of severe CAP with emphasis on prognosis in patients admitted to an ICU. *Intensive Care Med* 1995;21:24–31.
- Lieberman D, Schlaeffer F, Boldur I, Lieberman D, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. *Thorax* 1996;51:179–84.
- Lode H, Schaberg T, Mauch H. Management of community-acquired pneumonia. *Curr Opin Infect Dis* 1996;9:367–71.
- Lode H, Schaberg T, Raffenberg M. Therapie der nosokomialen Pneumonie. *Dtsch Med Wochenschr* 1997;122:93–6.
- Lode H. Infektionen der Atemwege – wann besteht eine Indikation zur Antibiotika-Therapie? *Pneumologie* 1990;44:763–6.
- Lode H. Sequential i.v./oral moxifloxacin treatment of patients with severe community-acquired pneumonia. *Resp Med* 2003;97:1134–42.
- Luna CM, Vujacich P, Niederman MS, Vay C, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. *Chest* 1997;111:676–85.
- Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. *Clin Infect Dis* 2000;31:383–421.
- Mandell LA, Niederman M. The Canadian Community-Acquired Pneumonia Consensus Conference. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. *Can J Infect Dis* 1993;4:25.
- Marrie TJ, et al. A controlled trial of a critical pathway for treatment of CAP (the CAPITAL Study). *JAMA* 2000;283:749–55.
- Marrie TJ, Peeling RW, Fine MJ, Singer DE, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. *Am J Med* 1996;101:508–15.
- Marston BJ, Lipman HB, Breiman RG. Surveillance for legionnaires disease: risk factors for morbidity and mortality. *Arch Intern Med* 1994;154:2417–22.
- Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalizations: results of a population-based active surveillance study in Ohio. *Arch Intern Med* 1997;157:1509–19.
- Matos CN, Ramos L, Dias C. Lung abscess. New perspectives in its treatment demonstrated with a clinical case. *Arch Med* 2002;16:141–5.
- Mayer J, Campbell GD Jr. ATS recommendations for treatment of adults with hospital-acquired pneumonia. *Infect Med* 1996;13:1027–9,1033–6,1044.
- McLaughlin RL. Managing the nonsurgical candidate with an empyema related to community-acquired lobar pneumonia. *Heart Lung* 2000;29:378–82.
- McGarvey RN, Harper JJ. Pneumonia mortality reduction and quality improvement in a community hospital. *Qual Rev Bull* 1993;19:124–30.
- Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. *JAMA* 1997;278:2080–4.
- Mehta RM, Niederman MS. Nosocomial pneumonia. *Curr Opin Inf Dis* 2002;15:387–94.
- Miravittles M, Espinosa C, Fernandez-Laso E, Martos JA, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. *Chest* 1999;116:40–6.
- Monso E, Ruiz J, Rosell A, Manterola J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. *Am J Respir Crit Care Med* 1995;152:1316–20.
- Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. *Ann Intern Med* 1994;121:947–52.
- Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1992;146:1067–83.
- Murray CJL, Lopez AD. Evidence-based health policy – lessons from the global burden of disease study. *Science* 1996;274:740–3.
- Naber K, Vogel F, Scholz H und eine Expertenkommission der PEG. Empfehlungen der Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V: Rationaler Einsatz oraler Antibiotika in der Praxis. *Chemother J* 1998;7:16–26.
- Nathwani D. Sequential switch therapy for lower respiratory tract infections. *Chest* 1998;113:2115S–218S.
- Nichol KL, Margolis KL, Wouremna J, et al. Effectiveness of influenza vaccine in the elderly. *Gerontology* 1996;42:274–9.
- Niederman MS, Gass JB, Campbell GD, et al. Guidelines for the initial empiric therapy of community-acquired pneumonia: Proceedings of an American Thoracic Society Consensus Conference. *Am Rev Resp Dis* 1993;148:1418–26.
- Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. American Thoracic Society. *Am J Respir Crit Care Med* 2001;163:1730–54.
- Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. *Sem Resp Infect* 2000;15:59–70.

- Niederman MS. Can optimal management prevent mortality in ventilator-associated pneumonia? *Crit Care Med* 2002;30:1916–7.
- Niederman MS. Community-acquired pneumonia: Management controversies, part 2. *J Resp Dis* 2002;23:147–57.
- Niederman MS. Hospitalized patients with community-acquired pneumonia: Overview of ATS guidelines and initial management. *Infect Dis Clin Pract* 1996;5(Suppl. 4):S142–7.
- Niederman MS. Nosocomial pneumonia in the elderly patient: Chronic care facility and hospital considerations. *Clin Chest Med* 1993;14:479–90.
- Niederman MS. ATS guidelines for treatment of adults with community-acquired pneumonia. *Infect Med* 1994;11:763–4,785–90.
- Niederman MS. How do we optimize outcomes for patients with severe community-acquired pneumonia? *Intensive Care Med* 2002;28:1003–5.
- Niederman MS. An approach to empiric therapy of nosocomial pneumonia. *Med Clin North-Am* 1994;78:1123–41.
- Niedermann MS. Hospitalized patients with community-acquired pneumonia: Overview of ATS guidelines and initial managements. *Infect Dis Clin Pract* 1996;5(Suppl. 4):142–7.
- Obaji A, Sethi S. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones? *Drugs Aging* 2001;18:1–11.
- Pallares R, Linares J, Vadillo M, Cabellos C, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. *N Engl J Med* 1995;333:474–80.
- Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Konsensuskonferenz : Cephalosporine zur parenteralen Applikation. *Chemother J* 1994;3:101–15.
- Pauwels RA, Buist AS, Calverley PM, Jenkins CR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Crit Care Med* 2001;163:1256–76.
- Plouffe JF, Breiman RF, Facklam RR for the Franklin County Pneumonia Study Group. Bacteremia with *Streptococcus pneumoniae*. *JAMA* 1996;275:194–8.
- Plouffe-JF, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. *Antimicrob Agents Chemother* 2000;44:1796–1802.
- Pollares R, et al. Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. *N Engl J Med* 1995;333:474–80.
- Reed WW, et al. Sputum gram's stain in community acquired pneumococcal pneumonia a meta-analysis. *West J Med* 1996;165:197–204.
- Rello J, Jubert P, Valles J, Artigas A, et al. Evaluation of outcome for intubated patients with pneumonia due to *Pseudomonas aeruginosa*. *Clin Infect Dis* 1996;23:973–8.
- Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. *JAMA* 1995;273:957–60.
- Saito A, et al. Clinical study on levofloxacin in the field of internal medicine. *Chemotherapy (Tokyo)* 1992;40:147–69.
- Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. *JAMA* 1995;274:1852–7.
- Sherk PA, Grossman RF. The chronic obstructive pulmonary disease exacerbation. *Clinics Chest Med* 2000;21:705–21.
- Siegel RE, Halpern NA, Almenoff PL, Lee A, et al. A prospective randomized study of inpatient iv antibiotics for community-acquired pneumonia. *Chest* 1996;110:965–71.
- Soejima R, et al. Comparative study of levofloxacin and ofloxacin in bacterial pneumonia by the double blind method. *Chemotherapy (Tokyo)* 1992;40:121–46.
- Stout JE, Yu VL. Legionellosis. *N Engl J Med* 1997;337:682–7.
- Tew J, et al. Bacterial or non-bacterial pneumonia: accuracy of radiographic diagnosis. *Radiology* 1977;124:607–12.
- The British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. *Br J Hosp Med* 1993;49:346–50.
- Vogel F, Charpentier C. Therapieempfehlungen bei Atemwegsinfektionen. *Chemother J* 1998;7:102–6.
- Vogel F, Stille W, Tauchnitz C, Stolpmann R. Positionspapier zur Antibiotika-Therapie in der Klinik. *Chemother J* 1996;5:23–7.
- Worth H, Adam D, Handrick W, Leupold W, et al. Prophylaxis and therapy of bronchial infections: Recommendations by the German Airways League in the German Pneumological Society. *Med Klin* 1997;92:699–704.

## Kapitel 5 – Intraabdominelle Infektionen

### Galle

- Aboud PA, et al. Predictors of common bile duct stones prior to cholecystectomy: a meta-analysis. *Gastrointest Endosc* 1996;44:450–5.
- Kiesslich R, Holfelder M, Will D, Hahn M, et al. Interventionelle ERCP bei Patienten mit Cholestase: Häufigkeit und Antibiotikaresistenz der biliären Keimbeseidlung. *Z Gastroenterol* 2001;39:985–92.
- Kiesslich R, Will D, Hahn M, Nafe B, et al. Levofloxacin versus Ceftriaxon in der Therapie der akuten Cholangitis – ein prospektiv randomisierter Vergleich. *Z Gastroenterol* 2003;41:5–10.
- Schwesinger WH, et al. Laparoscopic cholecystectomy for biliary tract emergencies: state of the art. *World J Surg* 1999;23:334–42.

### Peritonitis

- Bailey JA, Virgo KS, Dipiro JT, Nathens AB, et al. Aminoglykosides for intra-abdominal infection: Equal to the challenge. *Surg Infect* 2002;4:315–35.
- Barie PS, Vogel SB, Dellinger EP, Rotstein OD, et al. A randomized, double-blind clinical trial comparing cefipime plus metronidazol with imipenem in the treatment of complicated intraabdominal infections. Cefipime Intraabdominal Infection Group. *Arch Surg* 1997;132:1294–302.
- Barrell DT, Kenney PR, Slotman GJ, Burchard KW. Enterococcal bacteremia in surgical patients. *Arch Surg* 1985;120:57–63.
- Bone RC, Balk AR, Cerra FB, Dellinger RP, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 1992;101:1644–55.
- Bossa K, Reijnders K, Hulstaert F, Algra A, et al. Prognostic scoring systems to predict outcome in peritonitis and intraabdominal sepsis. *Br J Surg* 1997;84:1532.
- Burger JA, Schoffel U, Sach M, Jacobs E, et al. Effects of peritonitis exudates on chemotaxis and phagocytosis of human neutrophils. *Surg* 1995;161:647–53.

- Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intraabdominal infections. *Am J Surg* 1997;173:284–90.
- Christou NV, Barie PS, Dellinger EP, Waymack JP, et al. Prospective evaluation of management techniques and outcome. Surgical Infection Society Intraabdominal Infection Study. *Arch Surg* 1993;128:193–6.
- Dollinger P, Harnoss BM, Berger G, Häring R. Die postoperative Peritonitis. In: Häring R (Hrsg.). Peritonitis. Stuttgart: Georg Thieme Verlag, 1993:91–6.
- Edminston CE, Goheen MP, Kornhall S, Jones FE, et al. Fecal peritonitis: microbial adherence to seveal mesothelium and resistance to peritoneal lavage. *World J Surg* 1990;14:176–83.
- Farthmann EH, Schoeffel U. Principles and limitations of perioperative management of intraabdominal infections. *World J Surg* 1990;14:210–7.
- Halls GA. Antimicrobial practise. The management of infections and antibiotic therapy: a European survey. *J Antimicrob Chemother* 1993;31:985–1000.
- Hau T, Ohmann C, Wolmershauser A, Wacha H, et al., Group of the Surgical Infection Society of Europe. Planned relaparotomy versus relaparotomy on demand in the treatment of intraabdominal infections. *Arch Surg* 1995;130:1193–7.
- Hord CE. Treatment of intraabdominal infections: worldwide clinical trials. *Infect Dis Clin Pract* 1995;4:17–25.
- Kuo CH, Changchien CS, Chen JJ, Tai DI, et al. Septic acute cholecystitis. *Scand J Gastroenterol* 1995;30:272–5.
- Liss RH, Batchelor FR. Economic evaluation of antibiotic use and resistance – a perspective: report of task force 6. *Rev Infect Dis* 1987;8(Suppl. 3):297–312.
- Mazuski JE, Sawyer RG, Nathens AB, Dipiro JT, et al. for the Therapeutic Agents Committee of the Surgical Infection Society. The Surgical Infection Society Guidelines on Antimicrobial Therapy for Intra-Abdominal Infections: Evidence for Recommendations *Surg Infect* 2002;3:161–73.
- Mittelkötter U, Ender F, Reith HB, Thielemann H, et al. Antibiotische Behandlung der sekundären Peritonitis in Deutschland. Prospektive vergleichende Beobachtungsstudie zur Wirksamkeit und den Behandlungskosten. *Chirurg* 2003;74:1134–42.
- Nagy E, Foldes J. Inactivation of metronidazole by *Enterococcus faecalis*. *J Antimicrob Chemother* 1991;27:63–70.
- Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. *World J Surg* 1998;22:158–63.
- Nystrom PO, Bax R, Dellinger EP, Dominioni L, et al. Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe. *World J Surg* 1990;14:148–58.
- Offenbartl K, Bengmark S. Intraabdominal infections and gut origin sepsis. *World J Surg* 1990;14:191–5.
- Pallares R, Pujol M, Pena C, Ariza J, et al. Cephalosporins as risk factor for nosocomial *Enterococcus faecalis* bacteremia. *Arch Intern Med* 1993;153:1581–6.
- Polk HC Jr, Fink MP, Lavediere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-

- abdominal infection. Piperacillin/Tazobactam study group. *Am Surg* 1993;59:598–605.
- Rau B, Uhl W, Büchler MW, Beger HG. Surgical treatment of infected necrosis? *World J Surg* 1997;21:155–61.
- Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery – a prospective study. *Br J Surg* 1994;81:989.
- Schein M, Assalia A. The role of planned reoperation and laparostomy in severe intraabdominal infection: is a prospective randomized trial possible? *Theor Surg* 1994;8:38–42.
- Schoeffel U, Haering R, Farthmann EH. Diagnose und Behandlungsstrategie intraabdominaler Abszesse. *Zentralbl Chir* 1993;118:303–8.
- Schoeffel U, Jacobs E, Ruf G, Specht BU v, et al. Intraabdominal microorganisms and the severity of peritonitis. *Eur J Surg* 1995;161:501–8.
- Schoeffel U, Schweiger A, Jacobs E, Ruf G, et al. The role of endotoxin in the intraabdominal and the systemic inflammatory response in peritonitis. *Circ Shock* 1991;34:84.
- Sirinek K. Diagnosis and treatment of intra-abdominal abscesses. *Surg Infect* 2000;1:31–8.
- Solomkin JS, Dellinger EP, Christou NV. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. *Ann Surg* 1990;212:581–91.
- Solomkin JS, Reinhardt HH, Dellinger EP, Bohnen JM, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazol to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. *Ann Surg* 1996;223:303–15.
- Solomkin JS, Yellin AE, Rotstein OD, Christou NV, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. *Ann Surg* 2003;237:235–45.
- Teppeler H, McCarroll K, Gesser RM, Woods GL. Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam. *Surg Infect* 2002;4:337–49.
- Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. *Clin Infect Dis* 2003;37:997–1005.
- Wacha H. When antibiotics are indicated in pancreatitis. *Surg Infect Forum* 1997;II:NMIN LRHC.
- Wittmann D. Duration of antibiotic treatment in surgical infection of the abdomen. *Eur J Surg* 1996(Suppl):19–23.
- Wittmann DH, Wittmann-Taylor A. Scope and limitations of antimicrobial therapy of sepsis in surgery. *Langenbecks Arch Surg* 1998;383:15–25.
- Pankreas**
- Banks PA, Gerzof SG, Langevin RE. CT-guided needle aspiration of pancreatic infection: Accuracy and prognostic implications. *Int J Pancreatol* 1995;18:265–70.
- Baron T, Morgan DE. Acute necrotizing pancreatitis. *N Engl J Med* 1999;34:1412–7.
- Beger HG, Bittner R, Block S, Büchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. *Gastroenterology* 1986;91:433–8.
- Bradley EL III, Allen K. A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis. *Am J Surg* 1991;161:19–24.
- Büchler M, Malfertheiner P, Frieh H, et al. Human pancreatic tissue concentrations of bactericidal antibiotics. *Gastroenterology* 1992;103:1902–8.
- Büchler M, Malfertheiner P, Frieh H, et al. The penetration of antibiotics into human pancreas. *Infection* 1989;17:26–31.
- Drewelow B, Koch K, Otto C, Franke A, et al. Penetration of ceftazidime into human pancreas. *Infection* 1993;21:229–34.
- Gebhardt C, Bödeker H, Blinzler L, Kraus D, Hergdt G. Wandel in der Therapie der schweren akuten Pankreatitis. *Chirurg* 1994;65:33–41.
- Gerzof SG, Banks PA, Robbins AH. Early diagnosis of pancreatic infection by computed tomography-guided aspiration. *Gastroenterology* 1987;93:1315–20.
- Golub R, Siddiqi F, Pohl D. Role of antibiotics in acute pancreatitis: A meta-analysis. *J Gastrointest Surg* 1998;2:496–503.
- Isenmann R, Fleischer K, Büchler MW. Die Rolle der bakteriellen Infektion und Möglichkeiten der antibiotischen Behandlung bei der akuten Pankreatitis. *Verdauungskrankheiten* 1995;13:78–81.
- Koch K, Drewelow B, Brinckmann W. Die Pankreaspenetration von Ofloxacin – eine Pilotstudie. *Z Gastroenterol* 1993;31:587–91.
- Koch K, Drewelow B, Liebe S, Reding R, et al. Die Pankreasgängigkeit von Antibiotika. *Chirurg* 1991;62:317–21.
- Mithöfer K, Fernández-del Castillo C, Ferraro MJ, et al. Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis. *Gastroenterology* 1996;111:232–40.
- Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. *Surg Gyn Obstet* 1993;176:480–3.
- Ranson JHC. Etiological and prognostic factors in human acute pancreatitis: A review. *Am J Gastroenterol* 1982;77:633–8.
- Rünzi M, Holtman G. Akute Pankreatitis und Cholezystolithiasis. *Notfallmedizin* 2000;8:286–92.
- Rünzi M, Beger HG, Rau B, Isenmann R. Therapie mit Antibiotika bei schwerer akuter Pankreatitis. *Dtsch Ärztebl* 2002;99:A-116/B-97/C-94.
- Sainio V, Kempainen E, Puolakkainen P, et al. Early antibiotic treatment in acute necrotizing pancreatitis. *Lancet* 1995;346:663–7.
- Schwarz M, Isenmann R, Meyer H, Beger HG. Antibiotika bei nekrotisierender Pankreatitis. *Dtsch Med Wochenschr* 1997;122:356–61.
- Wilson C, Heath DI, Imrie CW. Prediction of outcome in acute pancreatitis: A comparative study of APACHE II, clinical assessment and multiple factor scoring systems. *Br J Surg* 1986;73:219–21.
- Clarridge JE, Pezzlo MT, Vosti KL, Weissfeld AS. Cumitec 2A. Laboratory diagnosis of urinary tract infections. Washington, DC: American Society for Microbiology, 1987.
- Daschner F, Chiarello LA, Dettkenkofer M, Facry J, et al. Hygiene and infection control of nosocomial catheter-associated urinary tract infection. In: Naber KG, Pechere JC, Kumazawa J, Khoury S, et al. (eds.). Nosocomial and health care associated infections in urology. Health Publication 2001. Plymouth, UK: Plymbridge Distributors, 2001:107–14.
- Garner JS, Jarvis WR, Emori TG, Horan TC, et al. CDC definitions for nosocomial infections, 1988. *Am J Infect Control* 1988;16:128–40.
- Gastmeier P, Kampf G, Wischniewski N, Hauer T, et al. Prevalence of nosocomial infections in representative German hospitals. *J Hosp Infect* 1998;38:37–49.
- Gatermann S, Podschun R, Schmidt H, Wittke J-W, et al. Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. MIQ 2: Harnwegsinfektionen. Stuttgart, Jena, Lübeck, Ulm: Gustav Fischer Verlag, 1997.
- Großer J. Einführung der Übersetzung der CDC-Definitionen für nosokomiale Infektionen 1988. *Z Ärztl Fortbild* 1991;85:817–27.
- Kouri T, Fogazzi G, Gant V, Hallander H, et al. European urinalysis guidelines. *Scand J Clin Lab Invest* 2000;60(Suppl. 231):1–96.
- Melekos MD, Naber KG. Complicated urinary tract infections. *Int J Antimicrob Agents* 2000;15:247–56.
- Members of the UTI Working Group: Naber KG (Chairman), Bergman B, Bishop MC, Bjerklund-Johansen TE, et al. EAU Guidelines for the management of urinary and male genital tract infections. *Eur Urol* 2001;40:576–88.
- Robert-Koch-Institut. Empfehlungen zur Prävention und Kontrolle Katheter-assoziiierter Harnwegsinfektionen. *Bundesgesundhbl.* 1999;42:806–9.
- Sheinfeld J, Erturk E, Spataro RF, Cockett ATK. Perinephric abscess: current concepts. *J Urol* 1987;137:191–4.
- Sklar AH, Caruana RJ, Lammers JE, Strauser GD. Renal infections in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 1987;10:81–8.
- Wagenlehner FME, Krcmery S, Held C, Klare I, et al. Epidemiological analysis of the spread of pathogens from an urological ward using genotypic, phenotypic and clinical parameters. *Int J Antimicrob Agents* 2002;19:583–91.
- Wagenlehner FME, Naber KG. Hospital-acquired urinary tract infections. *J Hosp Infect* 2000;46:171–81.
- Wagenlehner FME, Niemetz A, Naber KG. Erregerspektrum und Antibiotikaresistenz beim Harnwegsinfekt und Konsequenzen für die Antibiotika-Therapie. Untersuchungen bei stationären urologischen Patienten mit Harnwegsinfektionen (1994–2001). *Urologe A* 2003;42:13–25.
- Warren JW, Muncie HL Jr., Hall-Craggs M. Acute pyelonephritis associated with bacteriuria during long-term catheterization: a prospective clinicopathological study. *J Infect Dis* 1988;158:1341–6.
- Warren JW. Nosocomial urinary tract infections in principles and practice of medical intensive care. In: Geheb C (Hrsg.). Philadelphia: WB Saunders Company Harcourt Brace Jovanovich, Inc., 1993.
- Diabetes mellitus**
- Bouza E, Sanjuan R, Munoz P, Voss A, et al. and the cooperative Group of the European Study Group on nosocomial infections. I. Report on the microbiology workload, aetiology and anti-

- microbial susceptibility. *Clin Microbiol Infect* 2001;7:523–31.
- Chambers S, Lever M. Betaines and urinary tract infections. *Nephron* 1996;74:1–10.
- Geerlings SE, Stolck RP, Camps MJL, Nelfen PM, et al. Asymptomatic bacteriuria might be considered a diabetes complication in women with diabetes. *Diab Care* 2000;23:744–9.
- Hoepelman AIM. Urinary tract infection in patients with diabetes mellitus. *Int J Antimicrob Agents* 1994;3:113–6.
- Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. *Drug Int Clin Pharm* 1990;24:250–1.
- Leecker A, Kreft B, Sandmann J, Bates J, et al. Tamm-Horsfall-protein inhibits binding of S- and P-fimbriated *Escherichia coli* to human renal tubular epithelial cells. *Exp Nephrol* 1997;S:38–46.
- Nicolle LE, Friesen D, Harding GMK, Ross LL. Hospitalization for acute pyelonephritis in Manitoba Canada, during the period from 1989 to 1992: impact of diabetes, pregnancy and aboriginal origin. *Clin Infect Dis* 1996;22:1051–6.
- Schnapp D, Reid CJ, Harris A. Localization of expression of human beta defensin-1 in the pancreas and kidney. *J Pathol* 1998;189:99–103.
- Valore EV, Park CH, Quayle AJ, Wiles KR, et al. Human  $\beta$ -defensin-1: antimicrobial peptide of urogenital tissues. *J Clin Invest* 1998;101:1633–42.
- Niereninsuffizienz**
- Czock D, Böslers B, Rasche FM, Lukas R, et al. Vorschläge zur Dosisanpassung bei Niereninsuffizienz. *Nieren- und Hochdruckk.* 2003;2:74–80.
- Dettli L. Translation of pharmacogenetics to clinical medicine. *J Pharmacokinet Biopharm* 1973;1:403–18.
- Keller F, Bohler J, Czock D, Zellner D, et al. Individualized drug dosage in patients treated with continuous hemofiltration. *Kidney Int* 1999;Suppl. 72:29–31.
- Kunin CM. A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. *Ann Intern Med* 1967;67:151–8.
- Vogtlander NP, van Kasteren ME, Natsch SB, Kulberg J, et al. Failure of prescribers to adjust antibiotic dose to impaired renal function in daily clinical practice. *Br J Clin Pharmacol* 2002;53:557.
- Nierentransplantation**
- Maraha B, Bonten H, van Hooff H, Fiolet H, et al. Infections complications and antibiotic use in renal transplant recipients during a 1-year following up. *Clin Microbiol Infect Dis* 2001;7:619–25.
- Ringden O, Myrenfords P, Kintmalm G. Nephrotoxicity by co-trimoxazol and cyclosporine in transplanted patients. *Lancet* 1984;I:1016.
- Tockoff-Rubin NE, Rubin RH. Urinary tract infection and the immunocompromised host: UTI in renal transplant patients. In: Bergan T, Karger B (edit.). *Urinary tract infections*. 1997:34–6.
- Allgemeine Therapieempfehlungen**
- Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2002. *MMWR* 2002;51:48–51.
- Fünfstück R, Stein G, Naber KG, Hacker J, et al. Harnwegsinfektionen. *Nephrologie – Teil 3. Med Klin* 2003;98:377–87.
- Hoyme UB. Standortbestimmung zur Therapie urogenitaler Infektionen in der Gynäkologie und Geburtshilfe. *Frauenarzt-Seminar des Frauenarztes* 1999;5:690–4.
- Naber KG, Fünfstück R, Hofstetter A, Brühl P, et al. Empfehlungen zur antimikrobiellen Therapie von Infektionen der Nieren und des Urogenitaltrakts bei Erwachsenen. *Chemother J* 2000;9:193–9.
- Naber KG, Bergmann B, Bishop MC, Bjerklund Johansen TE, et al. EAU guidelines for the management of urinary and male genital tract infections. *Eur Urol* 2001;40:576–88.
- Penicilline**
- Adam D, Daschner F, Springsklee M. Sulbactam-geschützte Beta-Lactamantibiotika bei der Behandlung bakterieller Infektionen. Klinische und bakteriologische Ergebnisse. *Chemother J* 1995;4:129–37.
- Ball AP, Fox C, Ghosh D. Sultamicillin (CP-49,952): evaluation of two dosage schedules in urinary infection. *J Antimicrob Chemother* 1984;14:395–401.
- Benken N, Wöhr M, Echte L, Göbel C, et al. Sulbactam/Ampicillin + Gentamicin im Vergleich zu Mezlocillin + Gentamicin bei der Behandlung nosokomialer urologischer Infektionen. *Urologe B* 1996;36:207–11.
- Die Sulbactam/Ampicillin-Multicenter-Studien-gruppe, Lode H, Springsklee M. Klinische Ergebnisse mit Sulbactam/Ampicillin in einer multizentrischen Studie an 425 Patienten. *Med Klin* 1989;84:236–41.
- Leigh DA, Freeth M, Bradnock K, Marriner JM, et al. Augmentin (amoxicillin and clavulanic acid) therapy in complicated urinary tract infections due to beta-lactamase-producing bacteria. *J Antimicrob Chemother* 1981;7:229–36.
- Naber KG, Savov O, Hans Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. *Int J Antimicrob Agents* 2002;19:95–103.
- Naber KG, Wittenberger R. Behandlung von Harnwegsinfektionen mit Penicillinen. *Fortschr Antimikr Antineopl Chemother* 1985;4:6:1545–61.
- Neu HC, Wilson APR, Grüneberg RN. Amoxicillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. *J Chemother* 1993;5:67–94.
- Cephalosporine**
- Banfi A, Gabriele G, Hill-Juarez JM, Kaufman A, et al. Multinational comparative trial of ceftibuten and trimethoprim/sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. *Pediatr Infect Dis J* 1993;12(Suppl.):S84–91.
- Biemond A, de Fijter CWH, Meulen J v.d., et al. Oral treatment of complicated urinary tract infections: Cefitbuten (Sch39729) versus trimethoprim-sulfamethoxazole (TMP-SMZ). *Abstract. Neth J Med* 1991;39:A43.
- Elliott M. Oral ceftibuten as step-down therapy after parenteral 3rd-generation cephalosporin treatment for serious infection. *Can J Infect Dis* 1995;6(Suppl. C):242C.
- Giamarellou H. Clinical experience with the fourth generation cephalosporins. *J Chemother* 1996;8:91–104.
- Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. *Lancet* 1988;1:1305–9.
- Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, et al. and the Protocol 021 Study Group. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. *Urology* 2002;60:16–22.
- Mandell LA, Bergeron MG, Ronald AR, Vega C, et al. Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: A randomized, double-blind study. *J Infect Dis* 1989;160:433–41.
- Naber KG, Bauernfeind A. Behandlung des komplizierten Harnwegsinfektes mit parenteralen Cephalosporinen. *Fortschr Antimikr Antineopl Chemother* 1982;1:229–35.
- Naber KG, Bischoff W, Huber K, Tölch H-U, and the Cefax Study Group. Open, randomised, multicentre study with cefuroxime axetil (CFX) versus ofloxacin (OFX) in women with uncomplicated pyelonephritis. Poster # M 238. 2nd European Congress of Chemotherapy and 7th Biennial Conference on Anti-infective Agents and Chemotherapy, Hamburg, Germany, May 10-13, 1998. *Antiinfect Drugs Chemother* 1998;16(Suppl. 1):M 238.
- Naber KG, Dette GA, Kees F, Knothe H, et al. Aztreonam im Vergleich zu Cefotaxim bei der Behandlung von komplizierten Harnwegsinfektionen. *Fortschr Antimikr Antineopl Chemother* 1985;4-8:1969–79.
- Naber KG, Schoenwald S, Hauke W. Cefpodoximproxetil bei Patienten mit akuter unkomplizierter Pyelonephritis. Internationale, prospektive, randomisierte Vergleichsstudie versus Ciprofloxacin unter Praxisbedingungen. *Chemother J* 2001;10:29–34.
- Naber KG. Therapie komplizierter Harnwegsinfektionen mit Ceftrizoxim im Vergleich zu Ceftriaxon. *Z Antimikr Antineopl Chemother* 1983;1:41–50.
- Naber KG. Orale Cephalosporine/Cepheme zur Therapie von Harnwegsinfektionen bei Erwachsenen. In: Naber KG, Adam D, Grobecker H (Hrsg.). *Orale Cephalosporine/Cepheme im Vergleich. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie. FAC 12-1. München: Futuramed*, 1993;193–202.
- Patel ICH, Kaplan SA. Pharmacokinetic profile of ceftriaxone in man. *Am J Med* 1984;77:17–25.
- Sanchez-Ramos L, McAlpine KJ, Adair CD, Kautnitz AM, et al. Pyelonephritis in pregnancy: once-a-day ceftriaxone versus multiple doses of cefazolin. A randomized, double-blind trial. *Am J Obstet Gynecol* 1995;172:129–33.
- Sandberg T, Englund G, Lincoln K, Nielsson LG. Randomized double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. *Eur J Clin Microbiol Inf Dis* 1990;9:317–23.
- Scholz H, Naber KG, Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG). Einteilung der Oralcephalosporine. *Chemother J* 1999;8:227–9.
- Sharifi R, Geckler R, Childs S. Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections. *Am J Med* 1996;100(Suppl. 6A):76S–82.
- Fluorchinolone**
- Bailey RR, Begg EJ, Smith AH, Robson RA, et al. Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. *Clin Nephrol* 1996;46:183–6.
- Bailey RR, Lynn KL, Robson RA, Peddie BA, et al. Comparison of ciprofloxacin with netilm-

- icin for the treatment of acute pyelonephritis. *N Z Med J* 1992;105:102–3.
- Frankenschmidt A, Naber KG, Bischoff W, Kullmann K. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. *J Urol* 1997;158:1494–9.
- Naber KG, Adam D unter Mitwirkung einer Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Einteilung der Fluorchinolone. *Münch Med Wschr* 1998;140:248–50, *Chemother J* 1998;7:66–8, *Fortschr Antimikr Antineopl Chemother (FAC)* 1998;16:103–7.
- Naber KG, Adam D. Classification of fluoroquinolones. *Int J Antimicrob Agents* 1998;10:255–7.
- Naber KG, Bartnicki A, Bischoff W, Hanus M, et al. Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. *Int J Antimicrob Agents* (im Druck).
- Naber KG, Landen H. Rapid resolution of symptoms with ciprofloxacin therapy in 3859 hospitalized patients with urinary tract infection. *Int J Antimicrob Agents* (im Druck)
- Naber KG. Welche Fluorchinolone sind für die Behandlung von Harnwegsinfektionen geeignet? *Chemother J* 2002;11(Suppl. 20):72–80.
- Richard GA, Childs S, Fowler C, Pittman W, et al. A comparison of levofloxacin (LVFX) and ciprofloxacin (cipro) for the treatment of complicated urinary tract infections (cUTI). *Clin Infect Dis* 1996;23:914.
- Richard GA. A comparison of levofloxacin and ciprofloxacin in treating acute pyelonephritis in adult women. 19th International Congress of Chemotherapy (ICC). Montreal, Canada, July 1995.
- Talan DA, Stamm WE, Hooton TM, Moran GJ, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. *JAMA* 2000;283:1583–90.
- Wagenlehner FME, Naber KG. In-vitro-Aktivität von fünf Fluorchinolonen, Gentamicin, Amoxicillin/Clavulansäure und Co-trimoxazol gegenüber Erregern von komplizierten Harnwegsinfektionen. Eine multizentrische Studie. *Chemother J* 2001;10:140–7.
- Carbapeneme**
- Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, et al. and the Protocol 021 Study Group. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. *Urology* 2002;60:16–22.
- Naber KG, Savov O, Hans Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. *Int J Antimicrob Agents* 2002;19:95–103.
- Aminoglykoside**
- Bailey RR, Lynn KL, Robson RA, Peddie BA, et al. Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. *N Z Med J* 1992;105:102–3.
- Bailey RR, Begg EJ, Smith AH, Robson RA, et al. Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. *Clin Nephrol* 1996;46:183–6.
- Naber KG, Förster FH. Langzeittherapie mit Tobramycin beim chronischen Harnwegsinfekt. *Infection* 1975;3(Suppl. 1):125–7.
- Prostatitis, Epididymitis**
- Bjerkklund Johansen TE, Grüneberg RN, Guibert J, Hofstetter A, et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. *Eur Urol* 1998;34:457–66.
- Naber KG, Busch W, Focht J, and the German Prostatitis Study Group. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. *Int J Antimicrob Agents* 2000;14:143–9.
- Naber KN, and the European Lomefloxacin Prostatitis Study Group. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. *Int J Antimicrob Agents* 2002;20:18–27.
- Naber KN. Antimicrobial treatment of bacterial prostatitis. *Eur Urol* 2003;43(Suppl. 2):23–6.
- Vahlensieck W, Hofstetter AG. Acute prostatitis and prostatic abscess. In: Weidner W, Madsen PO, Schiefer HG (eds.) *Prostatitis. Etiopathologie, Diagnosis and Therapy*. Berlin, Heidelberg, New York: Springer, 1994:133–48.
- Weidner W, Schiefer HG, Dalhoff A. Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. *Am J Med* 1987;82(Suppl. 4A):280–3.
- Weidner W, Schiefer HG, Brähler E. Refractory chronic bacterial prostatitis: a reevaluation of ciprofloxacin treatment after a median follow-up of 30 months. *J Urol* 1991;146:350–2.
- Weidner W, Naber KG. Empfehlungen zur Prostataklassifikation und Therapie. *Aktuelle Urologie* 1999;30:A132.
- Endometritis, Salpingitis, Tuboovarialabszess, Pelveoperitonitis**
- Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2002. *MMWR* 2002;51:48–51.
- Eschenbach DA, Buchanan TM, Pollak HM, et al. Polymicrobial etiology of acute pelvic inflammatory disease. *New Engl J Med* 1975;293:166–171.
- Hoyme UB. Tuboovarialabszess, Pelveoperitonitis und septischer Schock. *Gynäkologie* 2002;4:353–62.
- Hoyme, UB. Standortbestimmung zur Therapie urogenitaler Infektionen in der Gynäkologie und Geburtshilfe. *Frauenarzt-Seminar des Frauenarztes* 1999;5:690–4.
- Infektiologische Empfehlungen und Leitlinien zur Diagnostik und Therapie in Gynäkologie und Geburtshilfe. 3. aktualisierte Ausgabe. München: medifact-publishing, 2002:33ff.
- Jacobson L, Westrom L. Objectivized diagnosis of acute pelvic inflammatory disease. *AM J Obstet Gynecol* 1969;105:1088–90.
- Livingood III CH. Tubo-ovarian abscess. In: Mead PB, Hager WD, Faro S. *Protocols for infectious diseases in obstetrics and gynecology*. Second Edition. Malden: Blackwell Science Inc., 2000:412418.
- Martens MG, Gordon S, Yarborough DR, Faro S, et al. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. *South Med J* 1993;86:604–10.
- Roy S, Higareta I, Angel-Muller E, Ismail M, et al. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. *Infect Dis Obstet Gynecol* 2003;1:27–37.
- Sweet RL. *Pelvic Inflammatory Disease: Treatment*. In: Mead PB, Hager WD, Faro S. *Protocols for infectious diseases in obstetrics and gynecology*. Second Edition. Malden: Blackwell Science Inc., 2000:400–5.
- Tellado J, Woods GL, Gesser R, McCarroll K, et al. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections. *Surg Infect* 2002;4:303–14.
- Walker CK, Kahn JG, Washington AE, Peterson HB, et al. Pelvic inflammatory disease: meta-analysis of antimicrobial regimen efficacy. *J Infect Dis* 1993;168:969–78.
- Walker CK, Workowski KA, Washington AE, Soper D, et al. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. *Clin Infect Dis* 1999;28(Suppl. 1):29–36.
- Witte EH, Peters AA, Smit IB, van der Linden MC, et al. A comparison of pefloxacin/metronidazole and doxycycline/metronidazole in the treatment of laparoscopically confirmed acute pelvic inflammatory disease. *Eur J Obstet Gynecol Reprod Biol* 1993;50:153–8.

## Kapitel 7 – Haut, Weichgewebe, Knochen- und Gelenke

- Allard P, Stucker M, von Kopületzki G, Elgamall S, et al. Zyklische intravenöse Antibiose als effizientes Therapiekonzept des chronisch rezidivierenden Erysipels. *Hautarzt* 1999;50:34–8.
- Bilton BD, Zibari GB, McMillan RW. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. *Am J Surg* 1998;64:397–401.
- Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. *N Engl J Med* 1996;334:240–5.
- Bosshardt TL, Henderson VJ, Organ CH Jr. Necrotizing soft-tissue infections. *Arch Surg* 1996;131:846–54.
- Bradsher RW Jr, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. *Am J Med* 1984;77:63–7.
- Brown DR, Davis NL, Lepawsky M, et al. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. *Am J Surg* 1994;167:485–9.
- Elliott D, Kufera JA, Myers RAM. The Microbiology of necrotizing soft tissue infections. *Am J Surg* 2000;179:361–6.
- File TM Jr, Tan JS. Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections. *Rev Infect Dis* 1991;13(Suppl. 9):733–6.
- Gentry LO, Ramirez-Ronda CH, Rodriguez-Noriega E, Thadepalli H, et al. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections: a multicenter trial. *Arch Intern Med* 1989;149:2579–83.
- Graham DR, Talan DA, Nicholds RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. *Clin Infect Dis* 2002;35:381–9.
- Grayson ML, Gibbons GW, Habershaw GW, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. *Clin Infect Dis* 1994;18:683–93.
- Grayson ML, McDonald M, Gibson K, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. *Clin Infect Dis* 2002;34:1440–8.
- Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococ-

- ccus aureus in a rural American Indian community. *JAMA* 2001;286:1201–5.
- Joseph WS. Treatment of lower extremity infections in diabetics. *Drugs* 1991;42:984–96.
- Joukhadar C, Klein N, Ditttrich P, Zeitlinger M, et al. Target site penetration of fosfomycin in critically ill patients. *J Antimicrob Chemother* 2003;51:1247–52.
- Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft tissue infections. *J Infection* 1991;22:37–40.
- Legat FJ, Maier A, Ditttrich P, Zenahlik P, et al. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. *Antimicrob Agents Chemother* 2003;47:371–4.
- Lipsky BA, Baker PD, Landon GC, et al. Antibiotic therapy for diabetic foot infections: Comparison of two parenteral-to-oral regimens. *Clin Infect Dis* 1997;24:643–8.
- McKinnon PS, Paladino JM, Grayson ML, Gibbons GW, Karchmer AW. Cost effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. *Clin Infect Dis* 1997;24:57–63.
- Muijers RB, Jarvis B. Moxifloxacin in uncomplicated skin and skin structure infections. *Drugs* 2002;62:967–73.
- Parish LC, Witkowski JA, Jungkind SL, et al. Treatment of cutaneous infections. Worldwide experience with ciprofloxacin. *Int J Dermatol* 1988;27:131–3.
- Parish LC, Routh HB, Miskin B, Fidelholtz J. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. *Int J Clin Pract* 2000;54:497–503.
- Parish LC, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. *J Clin Pract* 2000;54:497–503.
- Raz R, Miron D. Oral ciprofloxacin for treatment of infection following nail puncture wounds of the foot. *Clin Infect Dis* 1995;21:194–5.
- Sjöblom AC, Eriksson B, Jörup-Ronström C, Karkonen K, et al. Antibiotic prophylaxis in recurrent erysipelas. *Infection* 1993;21:390–3.
- Stevens DL, Smith LG, Bruss HB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. *Antimicrob Agents Chemother* 2000;44:3408–13.
- Stevens DL, Herr D, Lamperis H, Hunt JL, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant *Staphylococcus aureus* infections. *Clin Infect Dis* 2002;34:1481–90.
- Tan JS, Wishnow RM, Talan DA, Finegold SM, and the Piperacillin/Tazobactam Skin and Skin Structure Infection Study Group: Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. *Antimicrob Agents Chemother* 1993;37:1580–6.
- Tassler H. Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. *Am J Med* 1993;94:159–65.
- Wall DB, de Virgilio C, Black S, Klein SR. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infections. *Am J Surg* 2000;179:17–21.
- Wang J-H, Liu Y-C, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. *Clin Infect Dis* 1997;25:685–9.
- Kapitel 8 – Sepsis**
- Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis and septic shock. *Cochrane Database Syst Rev* 2000:CD001090.
- Astiz ME, Rackow EC. Septic shock. *Lancet* 1998;351:1501–5.
- Baden LR, Eisenstein BI. Impact of antibiotic resistance on the treatment of gram-negative sepsis. *Curr Infect Dis Rep* 2000;2:409–16.
- Balk RA. Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations. *Crit Care Clin* 2000;16:179–92.
- Baxter F. Septic shock. *Can J Anaesth* 1997;44:59–72.
- Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A perspective, randomised, double-blind, single-center study. Crit Care Med 1999;27:723–32.**
- Bodmann KF. Antimikrobielle Therapie. In: Schuster HP. Intensivtherapie bei Sepsis und Multiorganversagen. Berlin, Heidelberg, New York: Springer, 1996.
- Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. *Crit Care Med* 1996;24:1125–8.
- Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. *Chest* 1997;112:235–43.
- Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest*, 1992;101:1644–55.
- Brunkhorst R, Brunkhorst F. Procalcitonin and C3a: Nützlich zur Prognose und Verlaufsbeurteilung der Sepsis? *Intensivmed.* 2000;37:449–51.
- Dellinger RP. Current therapy for sepsis. *Infect Dis Clin North America* 1999;13:495–509.
- Ehrhard I, Sonntag HG. Epidemiologie der Meningokokken-Infektionen. *Mikrobiologie* 1998;8:162–7.
- Fourrier F, Jourdain M, Tournoys A. Clinical trial results with antithrombin III in sepsis. *Crit Care Med* 2000;9:38–43.
- Geerdes HF. Septicemia in 980 patients at an university hospital in Berlin: prospective studies during four selected years between 1979 and 1989. *Clin Inf Dis* 1992;15:991–1002.
- Hanetti G, Baumgartner JD, Glauser MP. Sepsis and septic shock. *Schweiz Med Wochenschr* 1997;127:489–99.
- Jacobs MR. Drug-resistant *Streptococcus pneumoniae*: reational antibiotic. *Am J Med* 1999;106:19–25.
- Kresken M, Hafner D, et al. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Chemotherapeutika in Mitteleuropa. *Chemother J* 2000;9:51–86.
- Kresken M, Hafner D. Prävalenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft „Resistenz“ in der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. aus dem Jahre 1995. *Chemother J* 1996;5:225–30.
- Mesters RM, Helterbrand J, Utterback BG, et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. *Crit Care Med* 2000;28:2209–16.
- MiQ-Richtlinie „Sepsis-Blutkulturdiagnostik“ 1997. Stuttgart, Jena: Gustav-Fischer-Verlag, 1997:1–44.
- Moser S, Fätkenheuer G, Salzberger B, et al. Die klinische Signifikanz positiver Blutkulturen zu einem Universitätsklinikum: eine prospektive Untersuchung zur Mikrobiologie. *Epidemiologie und Prognose* 1998;4:9.
- Naber K, Adam D. Einteilung der Fluorchinolone. *Chemother J* 1998;7:66–78.
- Nathwani D, Davey P. Strategies to rationalize sepsis management – a review of 4 years experience in Dundee. *J Inf* 1998;37:10–7.
- Niemiec PW, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. *Arch Surg* 1987;122:207–11.
- Reed RL. Contemporary issues with bacterial infection in the intensive care unit. *Surg Clin North Am* 2000;80:895–909.
- Rosenthal EJK. Epidemiologie von Septikämie-Erregern. *Dtsch Med Wochenschr* 1993;118:1269–75.
- Schotmüller H. Wesen und Behandlung der Sepsis. *Verh Dtsch Ges Inn Med* 1914;31:257.
- Scholz H, Naber K. Einteilung der Cephalosporine. *Chemother J* 1999;6:227–30.
- Schuster HP, Werdan K. Intensivtherapie bei Sepsis und Multiorganversagen. Berlin, Heidelberg: Springer, 2000.
- Simon D, Trenholme G. Antibiotic selection for patients with septic shock. *Crit Care Clin* 2000;16:215–31.
- Smith AL. Treatment of septic shock with immunotherapy. *Pharmacotherapy* 1998;18:565–80.
- Steinbrecher E, Sohr D, Nassauer A, et al. Die häufigsten Erreger bei Intensivpatienten mit nosokomialen Infektionen. Ergebnisse des Krankenhaus-Infektions-Surveillance-Systems (KISS). *Chemotherapy J* 2000;9:179–83.
- Trautmann M, et al. Computergestützte prospektive Erfassung nosokomialer Septikämien in einem Universitätsklinikum. *Hygiene und Medizin* 1997;22:467–73.
- Unertl K. Antimicrobial chemoprophylaxis of pneumonia in intensive care patients. *Chemotherapie J* 1996;5:89–93.
- Vincent JL, Preiser JC. Management of the critically ill patient with severe pneumonia. *J Chemother* 1999;11:524–9.
- Vogel F, Stille W, Tauchnitz C, et al. Positionspapier zur Antibiotikatherapie in der Klinik. *Chemother J* 1996;5:23–7.
- Vogel F, Naber K, Wacha H, et al. Parenterale Antibiotika bei Erwachsenen. *Chemother J* 1999;1:3–49.
- Werdan K, Pilz G. Supplemental immune globulins in sepsis: a critical appraisal. *Clin Exp Immunol* 1996;104:83–90.
- Wheeler AP, Bernard GR. Treating patients with severe sepsis. *N Engl J Med* 1999;340:207–14.
- Wittmann DH, Wittmann-Taylor A. Scope and limitations of antimicrobial therapy of sepsis in surgery. *Langenbecks Arch. Surg* 1998;383:15–25.
- Woltmann A, Hamann L, Ulmer AJ, et al. Molecular mechanism of sepsis. *Langenbecks Arch Surg* 1998;383:2–10.
- Wood MJ. Chemotherapy for gram-positive nosocomiale sepsis. *J Chemother* 1999;11:446–52.
- Zeitlinger MA, Marsik C, Georgopoulos A, Müller M, et al. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients. *Int J Antimicrob Agents* 2003;21:562–7. B IIb.
- Kapitel 9 – Endokarditis**
- Archer GL, Johnston JL, Vazquez GJ, Haywood HB. III. Efficacy of antibiotic combinations including rifampin against methicillin-resistant *Staphylococcus epidermidis*: in vitro and

- in vivo studies. *Rev Infect Dis* 1983;5(Suppl. 3):S538–42.
- Blaas SH, Elsner D, Glück T. Infektiöse Endokarditis. *Arzneimitteltherapie* 2002;11:362–74.
- Carey RB, Brause BD, Roberts RB. Antimicrobial therapy of vitamin B6-dependent streptococcal endocarditis. *Ann Intern Med* 1977; 87:150–4.
- Chambers HF, Miller RT, Newman MD. Right-sided *Staphylococcus aureus* endocarditis in intravenous drug abusers: two-week combination therapy. *Ann Intern Med* 1988;109: 619–24.
- Chuard C, Herrmann M, Vaudaux P, Waldvogel FA, et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant *Staphylococcus aureus* by antimicrobial combinations. *Antimicrob Agents Chemother* 1991;35:2611–6.
- Daniel WG, Mugge A, Martin RP, Lindert O, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. *N Engl J Med* 1991;324: 795–800.
- Erbel R, Rohmann S, Drexler M, Mohr-Kahaly S, et al. Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study. *Eur Heart J* 1988;9:43–53.
- Francioli P, Etienne J, Hoigne R, Thys JP, et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. *JAMA* 1992;267:264–7.
- Francioli P, Ruch W, Stambouliau D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. *Clin Infect Dis* 1995;21:1406–10.
- Friedberg CK, Rosen KM, Bienstock PA. Vancomycin therapy for enterococcal and *Streptococcus viridans* endocarditis. Successful treatment of six patients. *Arch Intern Med* 1968;122:134–40.
- Herzstein J, Ryan JL, Mangi RJ, Greco TP, et al. Optimal therapy for enterococcal endocarditis. *Am J Med* 1984;76:186–91.
- Hoppes WL. Treatment of bacterial endocarditis caused by penicillin-sensitive streptococci. *Arch Intern Med* 1977;137:1122–3.
- Karchmer AW, Archer GL, Dismukes WE. Rifampin treatment of prosthetic valve endocarditis due to *Staphylococcus epidermidis*. *Rev Infect Dis* 1983;5(Suppl. 3):S543–8.
- Karchmer AW, Moellering RC Jr., Maki DG, Swartz MN. Single-antibiotic therapy for streptococcal endocarditis. *JAMA* 1979;241: 1801–6.
- Korzeniowski O, Sande MA. Combination antimicrobial therapy for *Staphylococcus aureus* endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. *Ann Intern Med* 1982;97:496–503.
- Kowuah EF, Davies W, Oliver S, Stephens J, et al. Prosthetic valve endocarditis: early and late outcome following medical or surgical treatment. *Heart* 2003;89:269–72.
- Leitlinien zur Diagnostik und Therapie der infektiösen Endokarditis. *Chemother J*, voraussichtlich 2004
- Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant *Staphylococcus aureus* endocarditis. *Ann Intern Med* 1991;115: 674–80.
- Malacoff RF, Frank E, Andriole VT. Streptococcal endocarditis (nonenterococcal, non-group A): single vs combination therapy. *JAMA* 1979;241:1807–10.
- Naber CK, Bartel T, Eggebrecht H, Erbel R. Endokarditisdiagnostik heute, Duke-Kriterien oder klinische Einschätzung? *Herz* 2001;26: 379–90.
- Naber CK, Erbel R. Diagnosis of culture negative endocarditis: novel strategies to prove the suspect guilty. *Heart* 2003;89:241–3.
- Niebel J, Horstkotte D. Prevention of endocarditis 1998 – what is reliable? *Dtsch Med Wochenschr* 1998;123:1156–9.
- Perillo JE, Porst MH. Endocarditis due to resistant viridans streptococci during dental penicillin prophylaxis. *N Engl J Med* 1979;300: 296–300.
- Roberts SA, Lang SR. Short course treatment of penicillin-susceptible viridans streptococcal endocarditis with penicilline and gentamicin. *Inf Dis Clin Pract* 1993;2:191–4.
- Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. *Clin Infect Dis* 1998;27:1470–4.
- Small PM, Chambers HF. Vancomycin for *Staphylococcus aureus* endocarditis in intravenous drug users. *Antimicrob Agents Chemother* 1990;34:1227–31.
- Stambouliau D, Bonvehi P, Arevalo C, Bologna R, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. *Rev Infect Dis* 1991;13(Suppl. 2):S160–3.
- Tan JS, Kaplan S, Terhune CA Jr., Hamburger M. Successful two-week treatment schedule for penicillin-susceptible streptococcus viridans endocarditis. *Lancet* 1971;2:1340–3.
- Tompsett R, Hurst ML. Bacterial endocarditis: selected aspects of treatment. *Trans Am Clin Climatol Assoc* 1972;83:95–103.
- Westenfelder GO, Paterson PY, Reisberg BE, Carlson GM. Vancomycin-streptomycin synergism in enterococcal endocarditis. *JAMA* 1973;223:37–40.
- Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. *J Antimicrob Chemother* 1996;38: 507–21.
- Wilson WR, Thompson RL, Wilkowske CJ, Washington JA, et al. Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin. *JAMA* 1981;245:360–3.
- Wilson WR, Wilkowske CJ, Wright AJ, Sande MA, et al. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. *Ann Intern Med* 1984;100: 816–23.
- Wilson WR, Karchmer AW, Dajani AS, Taubert KA, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. *JAMA* 1995;274:1706–13.
- Wolfe JC, Johnson WD. Penicillin-sensitive streptococcal endocarditis. In-vitro and clinical observations on penicillin-streptomycin therapy. *Ann Intern Med* 1974;81:178–81.
- senschaftliche Verlagsgesellschaft, 1993.
- ASHP Commission on therapeutics. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. *Clin Pharm* 1992;11:483–513.
- Bates T, Siller G, Crathern BC, Bradley SP, et al. Timing of prophylactic antibiotics in abdominal surgery: trial of a pre-operative versus an intraoperative first dose. *Br J Surg* 1989;76: 52–6.
- Bergamini TM, Polk HC jr. The importance of tissue antibiotic activity in the prevention of operative wound infection. *J Antimicrob Chemother* 1989;23:301–13.
- Bieser U, Dietrich ES, Frank U, Schwarzer G, et al. Meta-analysis of the perioperative prophylaxis of ceftriaxone versus other cephalosporins. 5th Annual Cochrane Colloquium; 1997 Oct 8-12; Amsterdam.
- Birkigt HG, Beyer H. Generelle oder individuell kalkulierte Antibiotikaprophylaxe. *Zentralbl Chir* 1991;116:795–800.
- Boxma H, Broekhuizen T, Patka P, Oosting H. Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: the dutch trauma trial. *Lancet* 1996;347:1133–7.
- Burke JF. The effective period of prevention antibiotic action in experimental incisions and dermal lesions. *Surgery* 1961;50:161–8.
- Classen DC, et al. The timing of prophylactic administration of antibiotics and the risk of surgical wound infection. *N Engl J Med* 1992;326: 281–6.
- Cruse PJE, Foord R. The epidemiology of wound infection: A 10-year old prospective study of 62,939 wounds. *Surg Clin North Am* 1980;60: 27–40.
- Culver DH, Horan TC, Gaynes RP, Marone WJ, et al. Surgical wound infection rates produced by wound class, operative procedures and patients risk index. *Am J Med* 1991;91(Suppl. 3B):152–7.
- DÄB. B 13 73/74: Leitartikel Leitliniendiskussion. 1998;95:27.
- Dellinger EP, Gross PA, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. *Infect Control Hosp Epidemiol* 1994;15:182–8.
- Dellinger PE, Gross PA, Barrett TL, Krause PJ, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. *Clin Infect Dis* 1994;18:422–7.
- DGKH. Empfehlungen der DGKH zur perioperativen Antibiotikaprophylaxe. *Hyg Med* 1994;19:213–22.
- Dietrich ES, Bieser U, Frank U, Schwarzer G, et al. Ceftriaxone versus other cephalosporins for perioperative antibiotic prophylaxis: a meta-analysis of 43 randomized controlled trials. *Chemotherapy* 2002;48:49–56.
- Dormann AJ, Wigglinghaus B, Risius H, Kleimann F, et al. Antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG) – results from a prospective randomized multicenter trial. *Z Gastroenterol* 2000;38:229–34.
- Ebner W, Forster DH, Rüden H, Daschner F. Evidenzbasierte Empfehlungen zur perioperativen Prophylaxe. *Chirurg* 2000;71:912–7.
- Geffers C, Gastmeier P, Daschner F, Rüden H. Prävention postoperativer Wundinfektionen. *Zentralbl Chir* 2001;126:84–92.
- Gorecki P, Schein M, Rucinski JC, Wise L. Antibiotic administration in patients undergoing common surgical procedures in a community teaching hospital: the chaos continues. *World J Surg* 1999;23:429–32; discussion 433.
- Hauer T, et al. Nosokomiale Infektionen auf Intensivstationen. Eine bundesweite Prävalenzstudie (NIDEP). *Anaesthesist* 1996;15:1184–91.

## Kapitel 10 – Perioperative Antibiotika-Prophylaxe

### Allgemein

Adam D, Daschner F. Infektionsverhütung bei operativen Eingriffen: Hygienemaßnahmen und Antibiotika-Prophylaxe. Stuttgart: Wis-

- Isenmann R, Böhler M. Perioperative Prophylaxe in der Chirurgie. *Krankenhauspharmazie* 1992;6:287–90.
- Kaiser AB. Antimicrobial prophylaxis in surgery. *N Engl J Med* 1986;315:1129–38.
- Konsensuskonferenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Cephalosporine zur parenteralen Applikation. *Chemother J* 1994;3:101–15.
- Lewis RT, Weigand FM, Mamazza J, Lloyd-Smith W, et al. Should antibiotic prophylaxis be used routinely in clean surgical procedures: a tentative yes. *Surgery* 1995;118:742–6; discussion 746–7.
- Medina-Cuadros M, Sillero-Arenas M, Martinez-Gallego G. Surgical wound infections diagnosed after discharge from hospital: epidemiologic differences with in-hospital infections. *Am J Infect Control (St.Louis)* 1996;24:421–8.
- Mertens R. Methodologies and results of national surveillance. *Baillieres Clin Infect Dis* 1996;3:159–78.
- Miles AA, Miles EM, Burke J. The value and duration of defense reactions of the skin to the primary lodgement of bacteria. *Br J Exp Pathol* 1957;38:79–96.
- Morris PJ, Barnes BA, Burke JF. The nature of the „irreducible minimum“ rate of the incisional sepsis. *Arch Surg* 1966;92:367–70.
- NNIS National Infections Surveillance Report. NNIS-report, data summary from October 1986 – April 1996, issued May 1996. *Am J Infect Control (St.Louis)* 1996;24:380–8.
- Niederer C, et al. Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study. *Gastrointest Endosc* 1994;40:533–71.
- Ollenschläger G, Oesingmann U, Thomeczek C, Kolkmann FW. Ärztliche Leitlinien in Deutschland – aktueller Stand und zukünftige Entwicklungen. *Z Ärztl Fortbild Qual Sich* 1998;92:273–80.
- Peters G, Fischer R, Herrmann M. Perioperative Prophylaxe bei operativen Eingriffen. *Mitteilungen Dtsch Chir* 1995;5:9.
- Polk HC, Simpson CJ, Simmons BP, Alexander JW. Guidelines for prevention of surgical wound infection. *Arch Surg* 1983;118:1213–7.
- Raahave D, Friis-Møller A, Bjerre-Jepsen K. The infective dose of aerobic and anaerobic bacteria on postoperative wound sepsis. *Arch Surg* 1986;121:924–9.
- Ronveaux O, Mertens R, Dupon Y. Surgical wound infections surveillance: a result from the Belgian hospital network. *Acta Chir Belg* 1996;96:3–10.
- Ruckdeschel J, Sauerbruch T. Antibiotic prevention and therapy of infectious complications in ERCP. *Leber Magen Darm* 1992;22:173–6.
- Rüden H, Gastmeier P, Daschner FD, Schumacher M. Nosocomial and community-acquired infections in Germany. Summary of the results of the First National Prevalence Study (NIDEP). *Infections* 1997;25:199–202.
- Shapiro M. Perioperative prophylactic use of antibiotics in surgery: principles and practice. *Infect Control* 1982;3:38.
- Ullmann U, Wacha H. Infektionsprophylaxe bei Gelenkersatz in der Orthopädie. *Chemother J* 2003;12:57–60.
- Wacha H. Risikoadaptierte Antibiotikaprophylaxe in der Chirurgie. *Kliniker* 2002;31:299–303.
- Wacha H. Perioperative Antibiotika zur Verhütung bakterieller Infektionen. *Intensiv- und Notfallbehandlung* 2002;21:3–15.
- Risikofaktoren**
- Barrasa-Villar JJ, Domingo-Cuevas I, Vizmanos-Sevilla F. Utilización del índice NNSI para determinar el riesgo intrínseco de infección quirúrgica. *Med Clin (Barc)* 1996;107:767–71.
- Brunet F, et al. Risk factors for deep sternal wound infections after sternotomy: a prospective multicenter study. *J Thorac Cardiovasc Surg* 1996;111:1200–7.
- Dierssen T, Vicenta P, Seco JL, Rodrigo I, et al. Factores de riesgo asociados al desarrollo de infección de herida quirúrgica en un servicio de cirugía general. *Enferm Infecc Microbiol Clin* 1996;14:240–4.
- Fernandez-Arjona AM, Herruzo-Cabrera CR, Gomez-Sancha F. Four year study of the risk factors of surgical wound infection in 5260 traumatological patients. *Minerva Med* 1996;87:189–94.
- Fransen EJ, Maessen JG, Elenbaas TW, van Aarnhem EE. Enhanced preoperative C-reactive protein plasma levels as a risk factor for postoperative infections after cardiac surgery. *Ann Thorac Surg* 1999;67:134–8.
- Garibaldi RD, Cushing D, Lerer T. Risk factors for postoperative infections. *Am J Med* 1991;91(Suppl. 3B):158–63.
- Haley RW, Culver DH, Morgan M, White JW. Identifying patients at high risk surgical wound infection. A simple multivariate index of patient susceptibility and wound contamination. *Am J Epidemiol* 1985;121:206–15.
- Hussain M, Oppenheim BA, O'Neill P, Trembath C, et al. Prospective survey of the incidence, risk factors and outcome of hospital-acquired infections in the elderly. *J Hosp Infect* 1996;32:117–26.
- Jakob HG, Borneff-Lipp M, Bach A, von Pucker S, et al. The endogenous pathway is a major route for deep sternal wound infections. *Eur J Cardiothorac Surg* 2000;7:154–60.
- Kurz A, Sessler DU, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical wound infection and shorten hospitalization. *N Engl J Med* 1996;334:1209–15.
- Medina M, Sillero M, Martinez-Gallego G, Delgado-Rodriguez M. Risk factors of surgical wound infection in patients undergoing herniorrhaphy. *Eur J Surg Acta Chir* 1997;163:191–8.
- Moro ML, Carrieri MP, Tozzi AE, Lana S, et al. Risk factors for surgical wound infections in clean surgery: a multicenter study. Italian PRINOS Study Group. *Ann Ital Chir* 1996;67:13–9.
- Moulton MJ, Creswell LL, Cox JL, Rosenbloom M. Obesity is not a risk factor for significant adverse outcome after cardiac surgery. *Circulation* 1996;94:1187–92.
- Perl TM, Roy MC. Postoperative wound infections: risk factors and role of *Staphylococcus aureus* nasal carriage. *J Chemother* 1995;7(Suppl. 3):29–35.
- Poulson KB, Meyer M. Infection registration underestimates the risk of surgical wound infections. *J Hosp Infect* 1996;33:207–16.
- Rau HG, Mittelkötter U, Zimmermann A, Lachmann A, et al. Perioperative infection prophylaxis and risk factor impact in colon surgery. *Chemotherapy* 2000;46:353–63.
- Rebollo MH, Bernal JM, Llorca J, Rabasa JM. Nosocomial infections in patients having cardiovascular operations: a multivariate analysis of risk factors. *J Thor Cardiovasc Surg* 1996;112:908–13.
- Ronveaux O, Mertens R, Dupon Y. Surgical wound infection surveillance: results from the Belgian hospital network. *Acta Chir Belg* 1996;96:1:3–10.
- Sanderson PJ. Antimicrobial prophylaxis in surgery: microbiological factors. *J Antimicrob Chemother* 1993;31(Suppl. B):1–9.
- Velasco E, Martins CA, Goncalves VM, Dias LM, et al. Factores de risco para o desenvolvimento de infeccao da ferida operatoria em cirurgias oncologicas de cabeca e pescocco. *Rev Hosp Clin Fac Med Sao Paulo* 1995;50:85.
- Velasco E, Thuler LC, Martins CA, Dias LM, et al. Risk factors for infectious complications after abdominal surgery for malignant disease. *Am J Infect Control* 1996;24:1–6.
- Velasco E, Thuler LC, Martins CA, Dias LM, et al. Risk index for prediction of surgical site infection after oncology operations. *Am J Infect Control* 1998;26:217–22.
- Weigelt JA, Haley R, Seibert B. Factors which influence the risk of wound infection in trauma patients. *J Trauma* 1987;27:774–81.
- Abdominal**
- Adamek L, Mayer F, Wolf R, Raguse T. Nutzen der intraoperativen Antibiotikaprophylaxe bei Appendektomie. *Zentralbl Chir* 1991;116:801–8.
- Bruch HP, Schimmelpfennig H, Eckmann C. Antibiotikaprophylaxe in der Viszeralchirurgie. *Chirurg* 1997;68:951–5.
- Böhler MR, Malferteiner P, Frieß H, Bittner R, et al. The penetration of antibiotics into human pancreas. *Infection* 1989;17:20–5.
- Clarke IS, Condon RE, et al. Preoperative oral antibiotics reduce septic complications of colon operations: results of a prospective, double blind clinical study. *Ann Surg* 1979;186:251–9.
- Elliot DW. Prophylactic use of antibiotics in biliary surgery. *Southern Med J* 1977;70(Suppl. 1):31–5.
- Empanan C, Iturburu IM, Ortiz J, Mendez JJ. Infective complication after abdominal surgery in patients infected with human immunodeficiency virus: Role of CD4+ lymphocytes in prognosis. *World J Surg* 1998;22:778–82.
- Erttmann M, Krause R, Ullmann U. Pharmacokinetics of imipenem in patients undergoing major colon surgery. *Infection* 1990;18:367–71.
- Friese S, Pricker GJ, Willem FT, Loriaux SM. Single-dose prophylaxis in gynaecological surgery: amoxicillin/clavulanic acid versus the combination of cefuroxim and metronidazole in a randomized prospective comparison. *Eur J Obstet Gynaecol Reprod Biol* 1988;27:313–7.
- Gaffney PR. Wound infections in appendicitis: effective prophylaxis. *World J Surg* 1984;8:287–92.
- Gatehouse D, Dimock F, Burdon DW, Alexander-Williams J, et al. Bacterial flora of the stomach in patients requiring gastric operations. *Gut* 1977;18A:955.
- Glenny AM, Song F. Antimicrobial prophylaxis in colorectal surgery.
- Hord CE. Treatment of intraabdominal infections: worldwide clinical trials. *Infect Dis Clin Pract* 1995;4:17–25.
- Kujath P, Eckmann C. Oral prophylaxis with ciprofloxacin in colorectal and bile duct surgery. 37th ICACC, Toronto, 1997:Abstract J 162 (318).
- Lippert H, Gasting J. Antimicrobial prophylaxis in laparoscopic and conventional cholecystectomy. Conclusions of a large prospective multicenter quality assurance study in Germany. *Chemotherapy (Switzerland)* 1998;44:

- 355–63.
- McArdle CS, Morran CG, Pettit L, Gemell CG. Value of oral antibiotic prophylaxis in colorectal surgery. *Br J Surg* 1995;82:1046–9.
- Meijer WS, Schmitz PIM, Jeekel J. Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. *Br J Surg* 1990;77:283–90.
- Mittelkötter U. Antimicrobial prophylaxis for abdominal surgery: is there a need for metronidazole? *J Chemother* 2001;13(Spec No 1): 27–34.
- Mittelkötter U, Rau HG, Thiede A, Schildberg FW, et al. Perioperative Infektionsprophylaxe in der elektiven Kolonchirurgie: Klinischer Alltag in Deutschland. *Zentralbl Chir* 2001;126:799–804.
- Morris WT. Effectiveness of ceftriaxone versus cefoxitin in reducing chest and wound infections after upper abdominal operations. *Am J Surg* 1994;167:391–5.
- Rau HG, Zimmermann A, Lachmann A, Koehler L, et al. Perioperative Infektionsprophylaxe bei der elektiven Kolonresektion: Ceftriaxon vs. andere Beta-Lactame – eine Kosteneffektivitätsanalyse. *ZAC* 1998;197–208.
- Solomkin JS, Dellinger EP, Christou NV. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intraabdominal infections. *Ann Surg* 1990;212: 581–91.
- Stone HH, Hooper CA, Kolb LD, Geheber CE, et al. Antibiotic prophylaxis in gastric, biliary and colonic surgery. *Ann Surg* 1986;184:443.
- Vestweber KH, Grundel E. Efficacy and safety of piperacillin/tazobactam in intraabdominal infections. *Eur J Surg* 1994;573:57–60.
- Wacha H, Tau T, Dittmer R, Ohmann C, and the Peritonitis Study Group. Risk factors in intraabdominal infections: a prospective multicenter study. *Langenbecks Arch Surg* 1999;384:24–32.
- Wacha H. Differenzierte Antibiotikatherapie bei Peritonitis. *Acta Chir* 1991;26:320–4.
- Willis AT, Ferguson IR, Jones PH, Philips KD, et al. Metronidazol in prevention and treatment of bacteroides infections in elective colonic surgery. *Br Med J* 1977;1:607–10.
- Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden AJ, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. *Am J Surg* 2003;185: 45–9.
- Gynäkologie**
- Bohmert H. Technik der Sofortrekonstruktion nach modifizierter radikaler Mastektomie. In: Bohmert H. *Brustkrebs. Organerhaltung und Rekonstruktion*. Stuttgart: Georg Thieme Verlag, 1989:188–219.
- Duff P. Prophylactic antibiotics for hysterectomy. In: Mead PB, Hager WD, Hager S, Faro S. *Protocols for infectious diseases in obstetrics and gynecology*. Second edition. Malden: Blackwell Science, 2000:471–81.
- FOMWF. Leitlinie der FOMWF zur perioperativen Antibiotikaprophylaxe. *Frauenarzt* 1998;39: 680.
- Hirsch HA. Antibiotikaprophylaxe bei gynäkologischen Operationen. *Gynäkologe* 1988;21: 39–45.
- Hoyme UB, Bühler K, Walz KA, Winkler UH, et al. Perioperative Prophylaxe in der Mammachirurgie: Clindamycin versus Cefuroxim. *Zentralbl Gynäkol* 1993;115:77–9.
- Ledger WJ. Prophylactic antibiotics. In: Mead PB, Hager WD. *Infection protocols for obstetrics and gynecology*. Montvale: Medical Economics Publishing, 1992:272–6.
- Saez-Llorens X, Ah-Chu MS, Castano E, Cortes L, et al. Intrapartum prophylaxis with ceftriaxone decreases rates of bacterial colonization and early-onset infection in newborns. *Clin Infect Dis* 1995;21:876–80.
- Schönheit K, Hoyme UB. Die perioperative Antibiotikaprophylaxe erscheint in Bezug auf Harnwegsinfektionen optimierbar. Ergebnisse des randomisierten Vergleichs eines Aminopenicillins mit einem Cephalosporin der zweiten und einem der dritten Generation. *Frauenarzt* 2000;4:471–81.
- Von Mandach U, Huch R, Malinverni R, Huch A. Ceftriaxone (single dose) versus cefoxitin (multiple doses): success and failure of antibiotic prophylaxis in 1052 cesarean sections. *J Perinat Med* 1993;21:385–97.
- Urologie**
- Blumenberg EA, Abrutyn E. Methods for reduction of urinary tract infection. *Curr Opin Urol* 1997;7:47–51.
- Brühl P, Plassmann D. Zur Wertbemessung der perioperativen antibiotischen Infektionsprophylaxe bei der transurethralen Prostatachirurgie. In: Häring R (Hrsg.). *Infektionsverhütung in der Chirurgie*. Berlin: Blackwell Wissenschaft, 1991:
- Bruns T, Höchel S, Tauber R. Perioperative Antibiotikaprophylaxe in der operativen Urologie. *Urologe* 1998;38:269–72.
- Burke JP, Garibaldi RA, Britt MR, et al. Prevention of catheter-associated urinary tract infections: Efficacy of daily meatal care regimens. *Am J Med* 1981;70:655–8.
- Larsen EH, Gasser TC, Madsen PO. Antibiotikaprophylaxe bei operativen Eingriffen in der Urologie. *Extracta urologica* 1989;12:Heft 6.
- Naber KG. Antibakterielle Chemoprophylaxe bei transurethraler Resektion der Prostata. *Akt Urol* 1987;18(Sonderheft):34–7.
- Pearl EMS, Roehrborn CG. Antimicrobial prophylaxis prior to shock wave lithotripsy in patients with sterile urine before treatment: Meta-analysis cost effectiveness? *Urologe* 1997;49: 679–86.
- Schön G, Tawassoli N. Perioperative Antibiotikaprophylaxe bei der radikalen retropubischen Prostataktomie. *Urologe (B)* 1998; 38:522–4.
- Shearman CP, Silverman SH, Johnson M, Young CH, et al. Single dose, oral antibiotic cover for transurethral prostatectomy. *Br J Urol* 1988;62:424–38.
- Steiner T, Traue C, Schubert J. Perioperative Antibiotika-Prophylaxe bei transperitonealer Tumornephrektomie. *Urologe (A)* 2003; 42: 34–7.
- Unfall/Orthopädie**
- Espehaug B, Engesaeter LB, Vollset SE, Havelin LI, et al. Antibiotic prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. *J Bone Joint Surg Br* 1997;79:590–5.
- Hansis M. Antibiotikaprophylaxe in der Unfallchirurgie. *Chirurg* 1977;68:948–58.
- Ruett J, Althoff F. Cefuroximkonzentrationen im Serum, Kniegelenkflüssigkeit und Kapselgewebe bei perioperativer Anwendung vor orthopädischen Eingriffen unter Blutsperrung oder Blutleere. *Z Orthop* 1992;130:104–8.
- Herzchirurgie**
- Brunet F, et al. Risk factors for deep sternal wound infection after sternotomy: a prospective multicenter study. *J Thorac Cardiovasc Surg* 1996;111:1200–7.
- Gefäßchirurgie**
- Da Costa A, Kirkorian G, Cuchart M, et al. Antibiotic prophylaxis for permanent pacemaker implantation. *Circulation* 1998;97:1796–801.
- Florek HJ. Prinzipien der Antibiotikaprophylaxe in der Gefäßchirurgie. *Chirurg* 1994;68:955–7.
- Bissverletzungen**
- De Melker HE, De Melker RA. Dogbites publications on risk factors infections, antibiotics and primary woundclosure. *Ned Tijdschr Geneesk* 1996;22:1320–30.
- Gawenda M. Therapeutische Sofortmaßnahmen und Behandlungsstrategien bei Biss-Verletzungen. *Dtsch Ärzteztbl* 1996;93:B2177–81.
- Goldstein EJC. Bite wounds and infection. State of the art article. *Clin Infect Dis* 1992;14: 633–44.
- Koenig S, Aigner N. Bissverletzungen an der Hand und ihre besondere Stellung in der Unfallchirurgie. *Handchir Mikrochir Plast Chir* 1994;27:17–21.
- Malinverni R. DF-2, ein neuer gramnegativer Keim. *Schweiz Med Wochenschr* 1990;120:745–9.
- Scheuffle J, Knothe H. Hundebiss-Infektionen. *Umweltmedizin* 1981;4:57–8.
- Skura J, Willert C, Yogev R. Wound infection following dog bite despite prophylactic penicillin. *Infection* 1986;14:134–5.
- Zumla A. Management and microbiology of bites and burns. *Curr Opin Infect Dis* 1991;4: 639–49.
- Kapitel 11 – Meningitis**
- Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. *Ann Intern Med* 1998;129: 862–9.
- Bohr V, Hansen B, Jessen O, et al. Eight hundred and seventy-five cases of bacterial meningitis. I. Clinical data, prognosis, and the role of specialized hospital departments. *J Infect* 1983;7: 21–30.
- Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults: a review of 493 episodes. *N Engl J Med* 1993;328: 21–8.
- Enting RH, Spanjaard L, van de Beek D, Hensen EF, et al. Antimicrobial susceptibility of Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumoniae isolates causing meningitis in The Netherlands, 1993–1994. *J Antimicrob Chemother* 1996;38:777–86.
- Girgis NI, Farid Z, Mikhail IA, Farrag I, et al. Dexamethasone treatment for bacterial meningitis in children and adults. *Pediatr Infect Dis J* 1989;8:848–51.
- Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. *N Engl J Med* 2001;345:1727–33.
- De Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. *N Engl J Med* 2002;347:1549–56.
- Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. *Antimicrob Agents Chemother* 1995;39: 1988–92.

- McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. *JAMA* 1997;278:925–31.
- Nau R, Brück W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. *Trends Neurosci* 2002;25:38–45.
- Peltola H, Anttila M, Renkonen OV and the Finnish Study Group. Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. *Lancet (England)* 1989;1:1281–7.
- Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. *N Engl J Med* 1992;327:864–72.
- Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. *N Engl J Med* 1997;336:708–16.
- Saez-Llorens X, McCracken GH Jr. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. *Infect Dis Clin North Am* 1999;13:619–36.
- Scheld WM, Dacey RG, Winn HR, Welsh JE, et al. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis: alterations with penicillin and methylprednisolone. *J Clin Invest* 1980;66:243–53.
- Scholz H, Hofmann T, Noack R, Edwards DJ, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. *Chemotherapy* 1998;44:142–7.
- Spanos A, Harrell FE Jr, Durack DT. Differential diagnosis of acute meningitis: an analysis of the predictive value of initial observations. *JAMA* 1989;262:2700–7.
- Syrogiannopoulos GA, Lourida AN, Theodoridou MC, et al. Dexamethasone therapy for bacterial meningitis in children: 2- versus 4-day regimen. *J Infect Dis* 1994;169:853–8.
- Tauber MG, Khayam-Bashi H, Sande MA. Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. *J Infect Dis* 1985;151:528–34.
- Van Crevel H, Hijdra A, de Gans J. Lumbar puncture and the risk of herniation: when should we first perform CT? *J Neurol* 2002;249:129–37.
- Van de Beek D, de Gans J, Spanjaard L, Vermeulen M, et al. Antibiotic guidelines and antibiotic use in adult bacterial meningitis in the Netherlands. *J Antimicrob Chemother* 2002;49:661–6.
- Van de Beek D, Schmand B, de Gans J, et al. Cognitive impairment in adults with good recovery after bacterial meningitis. *J Infect Dis* 2002;186:1047–52.
- Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. *Antimicrob Agents Chemother* 1991;35:2467–72.
- concentrations in human aqueous humor following intravenous administration. *Chemotherapy* 1987;33:328–30.
- Behrens-Baumann W, Dobrinski B, Zimmermann O. Bakterienflora der Lider nach präoperativer Desinfektion. *Klin Monatsbl Augenheilkd* 1988;192:40–3.
- Behrens-Baumann W. Mycosis of the eye and its adnexa. *Developments in ophthalmology*. Basel: S. Karger AG, 1999:32 (with a contribution by R. Rütchel).
- Behrens-Baumann W. Magdeburger Dreistufenplan. [www.med.uni-magdeburg.de/augenklinik](http://www.med.uni-magdeburg.de/augenklinik), 1991–2003 (wird regelmäßig aktualisiert)
- Brinton GS, Topping TM, Hyndiuk RA, Aaberg TM, et al. Posttraumatic endophthalmitis. *Arch Ophthalmol* 1984;102:547–50.
- Gan IM, van Dissel JT, Beekhuis WH, Swart W, et al. Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis. *Br Ophthalmol* 2001;85:1289–93. EBM III
- Kain HL. Prinzipien in der Behandlung der Endophthalmitis. *Klin Monatsbl Augenheilkd* 1997;210:274–88.
- Masket S. Preventing, diagnosing, and treating endophthalmitis. *J Cataract Refract Surg* 1998;24:725–6.
- Schmidseeder E, Miño de Kaspar H, Klauf V, Kampik A. Posttraumatische Endophthalmitis nach penetrierenden Augenverletzungen. Risikofaktoren, mikrobiologische Diagnostik und funktionelle Ergebnisse. *Ophthalmologie* 1998;95:153–7.
- daily aminoglycoside administration. *Pharmaco-ther* 1997;17:810–4.
- Nicolau DP, McNabb J, Lacy MK, Quintiliani R, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. *Int J Antimicrob Agents* 2001;17:497–504.
- Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. *Ann Intern Med* 1996;124:884–90.
- Richerson MA, Ambrose PG, Bui KQ, Grant E, et al. Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered as either continuous or intermittent infusion with once-daily gentamicin. *Infect Dis Clin Pract* 1999;8:195–200.
- Slaughter RL, Cappelletty DM. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug-monitoring. *Pharmacoecon* 1998;14:385–94.
- Statistiken des Bundes KV 45 für 1. – 4. Quartal 2002.
- Stillfried D, Kamke K. Kassenärztliche Bundesvereinigung 2003.
- Strehl E, Brennscheidt U, Müller P. Antibiotikatherapie schwerwiegender Infektionen. *Krankenhaushygiene* 1995;8:330–5.
- Vogel F, Lüth A, Charpentier C. The impact of microbiological diagnostics on the antimicrobial treatment of hospitalised patients with infectious disease. *Eur J Med Res* 1995/96;1:312–4.
- Wenzel RP. The economics of nosocomial infections. *J Hosp Infect* 1995;31:79–87.

### Kapitel 13 – Pharmakoökonomie

Arnold M, Klauber J, Schellschmidt H. Krankenhausreport 2001. Bonn, 2001.

Brooks A, Ekleberry A, McMahon J, Begle R, et al. Evaluation of clinical practice guidelines on outcome of infection in medical intensive care unit patients. *Infect Dis Clin Pract* 1999;8:97–106.

Daschner F (ed). *Praktische Krankenhaushygiene und Umweltschutz*. 2. überarbeitete Auflage. Berlin: Springer, 1997.

Daschner FD. Cost-effectiveness in hospital infection control – lessons for the 1990. *J Hosp Infect Contr* 1989;13:325–36.

Dietrich ES, Joseph U, Vogel F, Howaldt S, et al. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany. *Infection* 1999;27:148–54.

Dietrich ES, Demmler M, Schulgen G, Fekec K, et al. Nosocomial pneumonia: A cost-of-illness analysis. *Infection* 2002;30:61–7.

Dietrich ES, Mast O, Fischer H, Hoppe-Tichy T, et al. und die Arbeitsgemeinschaft „Pharmakoökonomie von Antiinfektiva“. Vorschläge zur Planung, Durchführung und Publikation pharmakoökonomischer Evaluationen zu Antiinfektiva. *Chemother J* 2001;3:110–5.

Dietrich ES, Schmid M, Bucher A, Lemmen S, et al. Kostenreduktion in der Antibiotikatherapie. *Krankenhaushygiene* 1998;19:287–92.

Dietrich ES. Pharmakoökonomie nosokomialer Infektionen. In: Bodmann KF. *Therapiemanagement nosokomialer Infektionen*. Bremen: Uni-Med Verlag, 2001.

Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. *Am J Health-Syst Pharm* 1996;53:1141–50.

Hitt C, Klepser ME, Nightingale CH, Quintiliani R, et al. Pharmacoeconomic impact of once-

### Kapitel 11 – Augeninfektionen

Forestier F, Salvanet-Bouccara A, Leveques D, Junes P, et al. Ocular penetration kinetics of fosfomycin administered as a one-hour infusion. *Eur J Ophthalmol* 1996;6:137–42.

Philipp W, Kofler J. Untersuchung des Penetrationsvermögens von Fosfomycin in das Kammerwasser und den Glaskörper des Auges. *Klin Monatsbl Augenheilkd* 1986;189:240–2.

Adenis JP, Mounier M, Salomon JL, Denis F. Human vitreous penetration of imipenem. *Eur J Ophthalmol* 1994;4:115–7.

Behrens-Baumann W, Martell J. Ciprofloxacin